Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111224 | 0.85 | ALDH1A1 (0.35) | CETPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6718091 | 0.80 | ALDH1A1 (0.33) | CETPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8388701 | 0.80 | ALDH1A1 (0.32) | ALDH1A1EZH2SMN1; SMN2 | |
| SCHEMBL23027466 | 0.79 | ALDH1A1 (0.36) | CETPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL30813517 | 0.79 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11218997 | 0.79 | ALDH1A1 (0.36) | CETPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL3451196 | 0.77 | KDM4E (0.42) | ALDH1A1KDM4EMAPTLMNANPC1 | |
| SCHEMBL13930760 | 0.76 | DRD1 (0.37) | CETP | |
| SCHEMBL19520452 | 0.76 | CETP (0.33) | CETPMEN1KMT2A | |
| SCHEMBL10996324 | 0.75 | KMT2A (0.35) | HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | CETP 4579/4885ALDH1A1 2428/4885KDM4E 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.